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Target-specific oral anticoagulants (TSOACs) provide patients and healthcare providers with an alternative to vitamin
K antagonists (VKA). The TSOACs are of similar or superior efficacy to warfarin, but unlike VKAs, there are no approved
‘antidotes’ for rapid reversal of life-threatening bleeding on therapy. We report here the case of an 83-year-old
gentleman, who presented to the emergency department with severe gastrointestinal hemorrhage and coagulopathy
(hemoglobin: 5.3 g/dL and INR: 2.2) while on the direct thrombin inhibitor dabigatran. His coagulopathy reversed
rapidly after administration of 4-factor prothrombin complex concentrate (4 F-PCC), and after initial administration of 2
units of packed red blood cells, no further product transfusions were required. He was discharged 4 days later without
further complications.
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ReversalBackground
The U.S Food and Drug Administration (FDA) approved
dabigatran etexilate for prevention of stroke in patients
with nonvalvular atrial fibrillation, as well as for treat-
ment and prevention of recurrent venous thrombo-
embolism (VTE) in previously treated patients [1].
Dabigatran, 150 mg twice a day, has shown superiority
over warfarin with respect to its ability to prevent stroke
with a lower rate of life-threatening bleeding complica-
tions; however, dabigatran has an increased risk of
gastrointestinal bleeding [2]. Similar to all target-specific
oral anticoagulants (TSOACs) without a reversal agent,
unintentional bleeding remains a significant risk of treat-
ment. There has been some promise demonstrated in
the use of 4-factor prothrombin complex concentrate
(4 F-PCC) in dabigatran-associated hemorrhage in a
recent case series [3]. Here, we present a patient on
dabigatran who presented to the emergency department
(ED) with severe gastrointestinal hemorrhage, which was
treated with 4-factor prothrombin complex concentrate.* Correspondence: terrance.mcgovern@gmail.com
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An 83-year-old male with previous medical history of
hypertension, hyperlipidemia, coronary artery disease,
paroxysmal atrial fibrillation, transient ischemic attacks,
and a left atrial thrombus presented to the emergency
department with complaints of aphasia and bilateral
lower extremity weakness that began 1 h prior to arrival.
While en route to the hospital, the patient’s aphasia and
lower extremity weakness had resolved, and on arrival to
the ED, he had no acute complaints. On further ques-
tioning, the patient states that he had noticed malodor-
ous bowel movements and hematochezia for the past
5 days. At the time of presentation, the patient’s vital
signs were blood pressure: 128/51, pulse: 77, respiratory
rate: 18, pulse oximetry: 99%, and temperature: 100.6 °F.
The patient’s physical exam was significant for pallor,
+2/4 systolic murmur, bibasilar rales on lung ausculta-
tion, and guaic-positive maroon stool on rectal exam.
The patient’s home medication regimen was digoxin
0.125 mg daily, dronedarone 400 mg twice a day (BID),
atorvastatin 40 mg daily, enalapril 20 mg daily, metopro-
lol succinate 40 mg daily, pantoprazole 40 mg daily, and
dabigatran 150 mg BID. He stated that he was adherent
to his medications, including dabigatran, and had takenis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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tient’s routine laboratory analysis at initial presentation.
Based on the patient’s history, severe anemia and sus-
pected gastrointestinal hemorrhage, he was transfused 2
units of packed red blood cells and started on a proton
pump inhibitor; arguably, the most pressing issue was
reversing the patient’s coagulopathy. To replenish the
patient’s coagulation factors, he was given a dose of 25
units/kg (72 kg; 1,800 units) of 4 F-PCC based on insti-
tution protocol. Once stabilized in the ED, the patient
was admitted to the medical intensive care unit for
further evaluation and treatment. The patient’s repeat
coagulation profile the next day, after the administration
of the 4 F-PCC, showed an improvement in his coagula-
tion factors to prothrombin time (PT): 18.1 s, inter-
national normalized ratio (INR): 1.5, and activated partial
thromboplastin time (aPTT): 38.6 s and stabilization of
his hemoglobin at 7.6 g/dL and hematocrit to 22.9 g/dL
after the 2 units of packed red blood cells in the ED
(Table 1). Upper endoscopy revealed no active sites of
bleeding, and he did not require any further blood transfu-
sions during his inpatient hospitalization. He was subse-
quently discharged 4 days later after discontinuing his
dabigatran with a normalized coagulation profile and sta-
bilized anemia as demonstrated in Table 1.
Discussion
Dabigatran acts as a potent anticoagulant by preventing
thrombin’s conversion of fibrinogen to fibrin and inhibitsTable 1 Patient’s laboratory data
Lab Day 0 (ED) Day 1 Day 4 (discharge)
WBC 11.2 K/mm3 - -
Hgb 5.3 g/dL 7.6 g/dL 7.8 g/dL
Hct 15.7 g/dL 22.9 g/dL 23.4 g/dL
Platelet 142 K/mm3 - -
Na 162 meq/L - -
K 5.4 meq/L - -
Cl 127 meq/L - -
CO2 23 meq/L - -
BUN 39 mg/dL - -
Cr 1.45 mg/dL - -
Glucose 171 mg/dL - -
CrCl 35 to 40 mL/min - -
PT 24.0 s 18.1 s 16.7 s
INR 2.2 1.5 1.3
aPTT 57.2 s 38.6 s 35.4 s
Patient’s initial laboratory values in the emergency department and subsequent
hemoglobin/hematocrit and coagulation profile throughout the patient’s
inpatient hospitalization. CrCl, creatinine clearance; PT, prothrombin time; INR,
international normalized ratio; aPTT, activated partial thromboplastin time; Hgb,
hemoglobin; Hct, hematocrit; BUN, blood urea nitrogen.the ability of thrombin to activate factors V, VIII, and XI.
In patients with normal renal function (creatinine clear-
ance (CrCl) > 80 mL/min), dabigatran has a half-life of
13.8 h; however, when the CrCl < 30 mL/min, the half-
life extends to 27.5 h [4]. Dabigatran is primarily (80%)
renally excreted and reaches its peak concentration in
about 2 h [4,5].
In patients taking warfarin, evaluating the INR pro-
vides a quantitative means of assessing the extent of
anticoagulation for the patient. All coagulation assays
may be affected by dabigatran; however, the most com-
mon assays lack sensitivity in determining the extent of
anticoagulation. The PT and INR are both insensitive in
determining the extent of dabigatran activity, but there
can be small elevations in the patient’s INR in suprathera-
peutic ranges of dabigatran [6]. Thrombin clotting time
(TT) and ecarin clotting time (ECT) are the most accurate
and proportionally increase up to a value of 400 ng/mL of
dabigatran but are not routinely available in the emer-
gency department [6]. The most readily available coagula-
tion assay in the ED for monitoring the anticoagulant
effect of dabigatran is the aPTT. The dose–response curve
is curvilinear when looking at the drug concentration and
corresponding increase in aPTT [6]. While aPTT cannot
be relied upon to provide an exact measurement of dabi-
gatran in the blood, it can be qualitatively used to deter-
mine excessive anticoagulation.
Dabigatran is a viable alternative to warfarin for pre-
vention of stroke and systemic thromboembolism in
patients with nonvalvular atrial fibrillation with Class IB
evidence from the current 2014 AHA/ASA/HRS recom-
mendations [7]. Additionally, the use of dabigatran was
associated with lower risk of life-threatening and intra-
cranial bleeding when compared to warfarin; however,
the randomized evaluation of long-term anticoagulation
therapy (RE-LY) trial and a recent meta-analysis of ran-
domized controlled trials on the bleeding risk of dabiga-
tran demonstrated an increased risk for gastrointestinal
bleeding (RR: 1.51, 95% CI 1.23 to 1.84) [2,8].
4-factor prothrombin complex concentrate is indicated
for urgent reversal of vitamin K antagonists, such as
warfarin, by providing the vitamin-K-dependent factors
II, VII, IX, and X as well as protein C and S. Theoretic-
ally, the high concentration of these coagulation factors
should assist in thrombin activation and subsequent clot
formation. Experimental results have been variable when
analyzing nonactivated 4 F-PCC’s efficacy in treating
dabigatran-related bleeds. In animal models, there was
an improvement in bleeding time, but there was no ef-
fect on the coagulation assays [9,10]. In 2015, Hoffman
et al. used a cell-based model to demonstrate improve-
ment of multiple parameters of thrombin generation
after treatment with prothrombin complex concentrate
in the presence of therapeutic levels of dabigatran [11].
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mice, prothrombin complex concentrate did not signifi-
cantly reduce blood loss after a tail transection [12]. In a
separate murine model, prothrombin complex concen-
trate was able to prevent further intracerebral hematoma
growth in mice treated with dabigatran [13]. A 12-patient,
randomized, double-blind, placebo-controlled crossover
study evaluated the effects of 4 F-PCC on both dabigatran
and rivaroxaban reversal. The 12 healthy patients ran-
domly received dabigatran or rivaroxaban for 2.5 days and
then received 4 F-PCC (50 units/kg) or a placebo. After an
11-day washout period, the subjects received the other
anticoagulant for 2.5 days and again received either the
4 F-PCC (50 units/kg) or a placebo. After comparing the
aPTT, endogenous thrombin potential (ETP), lag time,
TT, and ECT in all the subjects, the administration of the
4 F-PCC had no influence on these coagulation assays for
the patients receiving dabigatran [14]. With the lack of
consensus and variability of results between animal
models, case reports, and small human trials, a group of
experts composed of members from the American Society
of Health-System Pharmacists (ASHP) met to propose
management considerations for patients bleeding while on
TSOAC [15]. After reviewing the available literature, their
first choice for reversal of dabigatran was activated PCC
(aPCC); however, their second choice was nonactivated
4 F-PCC, both of which are recommended with the ac-
knowledgement that their recommendation is based on
limited available clinical data [15]. The Thrombosis and
Hemostasis Summit of North America (THSNA) in 2012
also recognized the paucity of data in human trials and
could not come to a consensus on prothrombin complex
concentrate’s role in reversal of dabigatran; however, some
authors did feel that it would be reasonable in certain cir-
cumstances [16].
Despite conflicting data and case reports regarding the
utility of 4 F-PCC in the treatment of bleeding while on
dabigatran, the case presented here demonstrated a
normalization of the patient’s coagulation profile,
stabilization of his hemoglobin, and a positive clinical
outcome of the patient being discharged home without
incurring any further morbidity from his condition.
The extent of the patient’s hemorrhage had not reached
the point of causing objective signs of hemodynamic in-
stability, possibly due to his beta-blocker home medica-
tion. Nonetheless, having a hemoglobin of 5.3 g/dL in a
patient with significant cardiovascular pathology was
deemed reason enough to proceed with attempting to rap-
idly reverse the coagulopathic effect of dabigatran with
4 F-PCC. The patient may have been inadvertently
supratherapeutic due to his acute renal insufficiency
(CrCl: 35 to 40 mL/min). Dabigatran is renally excreted,
and in patients with renal impairment (CrCl < 30 mL/min),
the half-life can be prolonged up to 27.5 h [4]. In certaincircumstances where there is significant renal dysfunction
with a life-threatening bleed, dabigatran can be dialyzed be-
cause of its low plasma protein binding. It has been shown
that up to 62% of a single 50-mg dose of dabigatran can be
removed by dialysis in 2 h in end-stage-renal-disease pa-
tients on hemodialysis; this percentage increased to 68%
at 4 h [4]. Due to relative inexperience with emergent
extracorporeal therapy for dabigatran removal in life-
threatening bleeds, prior case reports have discovered a
‘rebound’ level of dabigatran after initial hemodialysis.
Dabigatran levels rebound in the terminal elimination
phase due to the large volume of distribution reportedly
as high as 87% in one single-center case series causing a
trend in coagulation assay levels to pre-hemodialysis
levels. Based on the rebound phenomena, the latest rec-
ommendation for hemodialysis for dabigatran reversal is
either prolonged intermittent hemodialysis or initial inter-
mittent hemodialysis followed by continuous renal re-
placement therapy [17,18]. In the case of life-threatening
hemorrhage but without significant renal impairment,
such as our patient, hemodialysis is less desired and other
reversal agents (i.e., 4 F-PCC) need to be explored and
considered.
Another consideration is the drug interaction that ex-
ists between dabigatran and dronedarone, which were
both taken by the patient prior to his hospitalization.
Dronedarone is a P-glycoprotein inhibitor while dabiga-
tran is a p-glycoprotein substrate. Co-administration can
increase dabigatran exposure up to 99%, leading to the
manufacturer’s recommendation to reduce the dabiga-
tran dose to 75 mg BID in moderate renal impairment
(CrCl 30 to 50 mL/min) [1,19]. The patient receiving full
dose dabigatran 150 mg BID while also sustaining acute
renal injury also contributed to excessive anticoagulation.
There remains no validated reversal agent to dabigatran-
related coagulopathy, but there may be soon. Currently
undergoing phase III clinical trials, idarucizumab is a
monoclonal antibody that targets dabigatran and may be a
potential solution. Two ex vivo studies comparing the use
of PCCs and idarucizumab’s ability to reverse dabigatran-
related bleeding demonstrated that idarucizumab cor-
rected PT and aPTT and reduced the plasma concentra-
tion of dabigatran to zero [20,21]. Additionally, the first-
in-human study also yielded positive results and marked
idarucizumab safe and tolerable in healthy males [22].
Conclusions
TSOACs provide an alternative choice to warfarin for
oral anticoagulation and will likely continue to be uti-
lized by physicians and their patients. Until there is a
commercially available ‘antidote’ to directly counteract
the TSOACs quickly and effectively, the risk of signifi-
cant or catastrophic hemorrhage remains. Here, we pre-
sented a case where 4-factor prothrombin complex
McGovern et al. International Journal of Emergency Medicine  (2015) 8:10 Page 4 of 4concentrate was used to expeditiously reverse dabigatran
in a patient with severe anemia due to gastrointestinal
hemorrhage. While more robust studies are needed to
determine the best method of reversal for TSOACs, the
use of 4-factor prothrombin complex concentrate should
be considered in situations where it is necessary to
counter the hemorrhagic complications of dabigatran.
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